Labcorp Scales PathAI’s Digital Pathology Platform Nationwide

Event summary

  • Labcorp expands collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.
  • The cloud-based technology enables fully digital workflows for case management, slide review, collaboration, and annotation, integrating AI-powered image analysis.
  • Labcorp will incorporate digital pathology workflows to support its precision medicine products.
  • The expansion builds on Labcorp's 2019 strategic investment in PathAI, which has advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.

The big picture

Labcorp's nationwide deployment of PathAI's digital pathology platform marks a significant step in modernizing pathology through AI and cloud-based technology. This move aligns with broader industry trends toward digital transformation in diagnostics, aiming to improve efficiency, collaboration, and patient outcomes. The collaboration also underscores the growing role of AI in clinical trial support and precision medicine, positioning Labcorp as a leader in integrating advanced technology into diagnostic workflows.

What we're watching

Adoption Pace
How quickly Labcorp can integrate AISight® Dx1 across its network and hospital collaborations will determine the platform's immediate impact on diagnostic efficiency.
Regulatory Compliance
Whether the FDA-cleared platform can maintain compliance while scaling, especially as AI insights become more integrated into routine care.
Competitive Edge
The extent to which this deployment differentiates Labcorp in the precision medicine space, potentially attracting more partnerships or clients.

Related topics

Diagnostics